Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 5/20 | 0.77 |
| ▸ | EPHB4 | P54760 | 4/20 | 0.77 |
| ▸ | EPHA2 | P29317 | 4/20 | 0.77 |
| ▸ | EGFR | P00533 | 15/20 | 0.76 |
| ▸ | FBP1 | P09467 | 2/20 | 0.76 |
| ▸ | AURKA | O14965 | 1/20 | 0.76 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.76 |
| ▸ | INSR | P06213 | 1/20 | 0.76 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.76 |
| ▸ | FLT4 | P35916 | 1/20 | 0.76 |
| ▸ | CLK1 | P49759 | 1/20 | 0.76 |
| ▸ | TEK | Q02763 | 1/20 | 0.76 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4531303 | 0.94 | KDR (0.72) | KDREPHB4EPHA2EGFRFBP1 | |
| SCHEMBL4359307 | 0.90 | EPHA2 (0.85) | KDREPHB4EPHA2EGFRFBP1 | |
| SCHEMBL4539126 | 0.90 | EGFR (0.74) | KDREPHB4EPHA2EGFRFBP1 | |
| SCHEMBL7814454 | 0.89 | EPHB4 (0.68) | KDREPHB4EPHA2EGFRFBP1 | |
| SCHEMBL7812296 | 0.89 | EPHB4 (0.68) | KDREPHB4EPHA2EGFRFBP1 | |
| SCHEMBL906997 | 0.87 | EPHA2 (1.00) | KDREPHB4EPHA2EGFRERBB2 | |
| SCHEMBL30505605 | 0.87 | EGFR (1.00) | KDREPHB4EGFRFBP1AURKA | |
| SCHEMBL2099106 | 0.87 | EGFR (1.00) | KDREPHB4EGFRFBP1AURKA | |
| Hydrochloric Acid SCHEMBL27887194 | 0.86 | EGFR (0.98) | KDREPHB4EGFRFBP1AURKA | |
| SCHEMBL1225064 | 0.86 | EPHA2 (0.87) | KDREPHB4EPHA2ERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | BOOJAMRA CONSTANTINE G | 2010-01-28 | — | — | US | disclosed |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | BOOJAMRA CONSTANTINE G | 2010-01-28 | — | — | US | disclosed |
| US-20090181930-A1 | KINASE INHIBITORY PHOSPHONATE ANALOGS | CANNIZZARO CARINA | 2009-07-16 | — | — | US | disclosed |
| US-20090181930-A1 | KINASE INHIBITORY PHOSPHONATE ANALOGS | CANNIZZARO CARINA | 2009-07-16 | — | — | US | disclosed |
| US-7452901-B2 | Anti-cancer phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-7452901-B2 | Anti-cancer phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-7417055-B2 | Kinase inhibitory phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| US-7417055-B2 | Kinase inhibitory phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| EP-0823900-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-12-27 | — | — | EP | disclosed |
| US-5770599-A | RECEPTOR TYROSINE KINASE INHIBITORS including 4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(2-morpholinoethoxy)quinazoline (gefitinib) | ZENECA LIMITED (GB) | 1998-06-23 | — | — | US | disclosed |
| EP-0823900-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1998-02-18 | — | — | EP | disclosed |
| WO-1996033980-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181930-A1 | KINASE INHIBITORY PHOSPHONATE ANALOGS | PIK3CA, PNKP, PIK3CB | KDR 860/4885EPHB4 3230/4885EPHA2 1802/4885 |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | PIK3CA, PHOSPHO1, PTEN | KDR 1628/4885EPHB4 3424/4885EPHA2 2144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.